# Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

> **NCT00087334** · PHASE1,PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** gefitinib
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00087334
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2005-11
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Withdrawn due to poor/low accrual
- **Last updated:** 2013-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087334, "Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00087334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*